Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Provides MetaMx Development Update

Marketwired December 1, 2015

Arch Biopartners Receives Orphan Drug Designation from FDA for AB569

Marketwired November 13, 2015

Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services

Marketwired October 21, 2015

Arch Biopartners: AB569 Successfully Completes Pre-Clinical Validation Studies

Marketwired September 17, 2015

Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides

Marketwired August 5, 2015

Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface

Marketwired August 4, 2015

Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface

Marketwired August 4, 2015

Arch Scientists Use 'BORG' Peptides to Improve Biocompatibilty of Polysulfone for Use in Dialysis

Marketwired July 23, 2015

Dr. Sheila Singh, MD PhD. Joins Arch Biopartners as Medical and Clincial Advisor

Marketwired June 8, 2015

Arch Biopartners 2015 AGM Results and Technology Status Update

Marketwired April 1, 2015

Arch Biopartners Identifies Candidate Drug to Treat Psuedomonas Respiratory Infections

Marketwired March 18, 2015

Arch Biopartners Announces Issuance of U.S. Patent for Peptide Solid Surface Interface

Marketwired February 25, 2015

Arch Biopartners Appoints Claude Allary to Board of Directors

Marketwired April 17, 2014

Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections

Marketwired March 28, 2014

Arch Biopartners Completes Private Placement

Marketwired March 25, 2014